Coordinación de Investigación en Salud, Mexico
imss.gob.mxTotal trials
97
Active
13
Phase 3
14
Total enrollment
31,507
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intravascular Hydrocortisone (stress dosage): 1 mg/k/dose each 8 hours for 5 days | — | — | — | — | — | 1 | |
| lipid injectable emulsion with Fish oil | — | — | — | — | — | 1 |
Next readouts
- 2026-06-30
- 2026-11
Top conditions
- Obesity7
- Hypertension4
- Covid194
- Type 2 Diabetes4
- Vitamin D3
- Insulin Resistance3
- Obesity, Childhood3
- Inflammation3
Frequently asked questions about Coordinación de Investigación en Salud, Mexico
- How many clinical trials does Coordinación de Investigación en Salud, Mexico have on ClinicalTrials.gov?
- Coordinación de Investigación en Salud, Mexico is listed as the lead sponsor on 97 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Coordinación de Investigación en Salud, Mexico's trials are in Phase 3?
- 14 of Coordinación de Investigación en Salud, Mexico's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Coordinación de Investigación en Salud, Mexico focus on?
- Coordinación de Investigación en Salud, Mexico's most-studied conditions on ClinicalTrials.gov are Obesity, Hypertension, Covid19, Type 2 Diabetes, Vitamin D.
- When are Coordinación de Investigación en Salud, Mexico's next clinical trial readouts?
- Coordinación de Investigación en Salud, Mexico has 2 upcoming primary-completion readouts tracked here; the soonest is “Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial”, expected around 2026-06-30.